MedReleaf Issues Response to Health Canada’s Proposals on Cannabis Regulation

MedReleaf (TSX:LEAF) issued a statement in response to the Canadian federal government’s proposals on the regulation of cannabis.

As quoted in the press release:

As a licensed producer of cannabis, our goal is to ensure consumers have access to all the facts and details necessary to make informed decisions when purchasing cannabis products. On this point, we believe Health Canada’s packaging and branding recommendations miss the mark. Defaulting to a tobacco-like regime fails to recognize fundamental differences between products, or to account for current and future variations in consumption methods, such as oils or capsules.

We believe the common-sense and true risk-based approach is to regulate cannabis in a way similar to alcohol and provide consumers the ability to distinguish between brands (and all they represent) including product types, qualities, varieties, effects, sources of origin and awards garnered. As a dedicated corporate partner in the delivery of legal and regulated cannabis products, we firmly believe that adult-focused branded packaging will also better differentiate legal products from black market offerings thereby serving a fundamental public policy objective.

While we applaud the government in making these recommendations accessible for public review, we ask Health Canada to work with us to further refine their recommendations. Finding a compromise position on potentially unsafe suggestions for branding, packaging, and labeling requirements is in the best interest of all Canadians.

Click here to read the full press release.

Source: investors.medreleaf.com